also demonstrated that the frequent loss of the CDKN2A could trigger the susceptibility to IFN-γ resistance via JAK2 gene deletion in melanoma (66), which was in line with our conclusion that high expression of CDKN2A potentially benefited from immunotherapy. The gene discussed is CDKN2A; the disease is melanoma.